Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Posted in AI Models in Healthcare, Artificial Intelligence - General, Artificial Intelligence Applications in Health Care, HealthCare IT, United States | 3 Comments

3 Responses

1. on January 26, 2022 at 5:32 PM | Reply IBM has reached an agreement to sell its Watson Health data and analytics business to the private-equity firm Francisco Partners — Leaders in Pharmaceutical Business Intelligence (LPBI) Group – New Human New Earth Communities

   […] IBM has reached an agreement to sell its Watson Health data and analytics business to the private-eq… […]

   Loading...

   
   
2. on January 28, 2022 at 10:18 AM | Reply 2012pharmaceutical

   WEDNESDAY
   Stephen J. Williams, Ph.D. sent the following message at 12:15 PM
   View Stephen J.’s profile
   Stephen J. Williams, Ph.D.
   Stephen J. Williams, Ph.D. 12:15 PM
   I as well am confused why a Partner firm like Francesco would see this fitting in their current operations unless they had another partner in mind
   Luis De La Cruz sent the following message at 12:28 PM
   View Luis’ profile
   Luis De La CruzStatus is reachable
   Luis De La Cruz 12:28 PM
   Being able to capture the response from many as they scratch their heads in trying to figure out how this move makes the scientific sense of taking IBM Watson Health to the next level?

   Yes, I agree FP does have a plan in place as their studies must have provided promise with a new set of Scientific minds to place their flavors of spice to integrate components that was lacking from in house IBM folks:

   The evaluation will continue as the Globalization of scientific health betterment continues.

   There is enough for everyone…
   John F. McCarthy sent the following message at 1:44 PM
   View John F.’s profile
   John F. McCarthyStatus is reachable
   John F. McCarthy 1:44 PM
   Agree with Stephen. My understanding is that Watson was positioned as a clinical decision support system. However, my recollection is that it had achieved limited success in the genetics realm but, found it was less useful in other clinical domains. Such clinical decision support is not the focus of LPBI and as such having difficulty see where the potential fit might be unless Francesco has a different direction in mind (per Luis). Otherwise, I do not see how LPBI assets would be of value to them. I don’t see the complementary perspective. |More like apples and oranges.
   Aviva Lev-Ari, PhD, RN sent the following message at 2:51 PM
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 2:51 PM
   I am off Zoom with Gregory who sold his KDnuggets
   https://www.kdnuggets.com/

   to an information syndicators for x10

   He told me that we need to develop a Contrastive Learning Model [Gap Analysis] between what LPBI offers and what WATSON Health assets potential is

   The reasons that IBM WATSON Health had limited success is relted to the fact that both Pharma R&D and Hospital Innovation Adoption WERE ALIENS TO IBM SOFTWARE DEVELOPMENT ENVIRONMENT

   PubMed was treated as THE gold mine

   A. PubMed is an archive of Reports of
   (1) experiments results
   (2) Clinical Trials results
   (3) NOTHING ELSE

   B. LPBI approach is different
   (1) combat life sciences and medical information explosion and its obsolescence by
   (2) Constantly updated CURATIONS that represent the Clinical interpretations of the scientific findings REPORTED in PubMed by Experts: MDs, PhDs, PharmD, and MD/PhDs
   (3) When LPBI IP asset classes:
   I. Journal articles
   II. Books
   III. e_Proceedings
   V. Gallery of Biological Images
   XII. NLP on our Books
   XIV. BLOCKCHAIN platform with all of the above, INDEXED on it
   THEN
   XI. Discovery across all above IP Asset classes will be enabled

   THESE VIRTUES LPBI bring to the Table of Francisco Partners – That will be the BRIDGES needed for them to ADD VALUE to Pharma and to Hospitals
   Download NFT – LPBI Portfolio of IP Valuation Aviva and SJW views final version.xlsx
   NFT – LPBI Portfolio of IP Valuation Aviva and SJW views final version.xlsx
   15 KB

   Download

   You added Gregory Piatetsky-Shapiro to this conversation
   Aviva Lev-Ari, PhD, RN sent the following messages at 3:14 PM
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 3:14 PM
   AFTER you study this attachment and you digest my message above – GO BACK to your opinion and RE-polish your Apple
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 3:56 PM
   Please All review

   https://pharmaceuticalintelligence.com/2022/01/26/ibm-has-reached-an-agreement-to-sell-its-watson-health-data-and-analytics-business-to-the-private-equity-firm-francisco-partners/

   IBM has reached an agreement to sell its Watson Health data and analytics business to the private-equity firm Francisco Partners
   pharmaceuticalintelligence.com • 8 min read
   Stephen J. Williams, Ph.D. sent the following message at 4:01 PM
   View Stephen J.’s profile
   Stephen J. Williams, Ph.D.
   Stephen J. Williams, Ph.D. 4:01 PM
   It is interesting you say repolish your ‘Apple’. Back in 80s IBM was the one who had the PC but passed on the market allowing APPLE to take over. They have I think problems there with short-sightedness or only looking at bottom line. It may be they had too many gaps in their analyses to make any sense of their algorithm. I am also curious why an Oracle Health did not make a bid (unless they did and got outbid). It would be good to hear from Fransico Partners CEO but they are not public so they don’t need to say anything
   Aviva Lev-Ari, PhD, RN sent the following message at 4:12 PM
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 4:12 PM
   I send a link to all the VIEWS published on WATSON Health SALE since 1/21/2022

   By far the MOST documented event in 2022.

   I claim that: Verily is developing AI based Health applications by employees that are MDs, ex-Pharma Exec and CS gurus

   IBM – developed WATSON Health in house by CS experts. Exporting PubMed DB was the premise without Domain Knowledge Experts and clinicians and Health Policy

   The View was monolithic:
   1. Health IT
   2. Digital Health
   3. Genomics

   HORSE COMPUTE POWER in place no Strategic vision of Directions in Healthcare and Pharma R&D
   Ofer Markman sent the following message at 4:32 PM
   View Ofer’s profile
   Ofer MarkmanStatus is online
   Ofer Markman 4:32 PM
   👍
   Aviva Lev-Ari, PhD, RN sent the following message at 4:38 PM
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 4:38 PM
   attn: John McCarty

   WHAT DID AVIVA CO IN DECISION SUPPORT – WHY she is uniquely qualified for the merge of LPBI Domain Knowledge and hers DSS algorithm design:

   ALL to read all these links:

   GO TO
   https://pharmaceuticalintelligence.com/founder/

   SCROLL to the bottom
   SEE all the live links

   START WITH

   Aviva’s
   Contributions to Design of Algorithm-based Decision Support Systems

   Aviva’s
   Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.

   THEN the domain knowledge LINKs

   THEN Re-Polish your Apple

   Scientific and Medical Affairs Chronological CV
   Technology Executive, Methodology and Decision Scientist, Functional CV
   Contributions to Design of Algorithm-based Decision Support Systems
   Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.
   HealthCare Delivery – Long Term Post Acute Care Nursing Management CV
   Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence
   List of Invited Lectures, 1983 -2004
   List of Publications, 1983 – 2004
   List of Publications, 2006 – Present
   Cardiovascular Diseases and Pharmacological Therapy: Curations, 2006 – 4/2018
   MedTech & Medical Devices for Cardiovascular Repair – Curations
   Stem Cells and Cardiac Repair: Content Curation & Scientific Reporting
   Regulatory Affairs: Publications on FDA-related Issues – Aviva Lev-Ari, PhD, RN
   Cancer Research: Curations and Reporting
   Autobiographical Annotations: Tribute to My Professors
   Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
   Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley
   Photography and The Arts

   Founder
   pharmaceuticalintelligence.com • 7 min read
   You added Justin Pearlman and Larry Bernstein to this conversation
   Aviva Lev-Ari, PhD, RN sent the following messages at 5:31 PM
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 5:31 PM
   WE NEED TO HASH our views

   Please all contribute paragraph of ideas vs Symbols
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 5:47 PM
   Please all review the PowerPoint we are working on to make the CASE for LPBI Group’s complementarities to WATSON Health

   Each please contribute two slides after you read ALL the attachments shares with you in this stream of messages
   Download LDLCruz_FP_LPBI-ALA_Edit[2] .pptx
   LDLCruz_FP_LPBI-ALA_Edit[2] .pptx
   442 KB

   Download

   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 6:54 PM
   FROM
   https://www.reddit.com/r/Futurology/comments/sazn5f/ibm_has_sold_off_watson_at_a_steep_discount_and/

   InterestinglyLucky
   ·
   3 days ago
   Wholesome
   I’m a scientist by training, and have actively followed IBM / Watson Health for several years.

   It was perhaps four or five years ago at a major scientific conference (it may have been ASCO or perhaps AACR for cancer research) I stopped by the flashy IBM / Watson Health booth, picked up a cool mug, and asked a question they had not good answer for: was there any peer-reviewed publication they could show me where Watson could help improve diagnosed cancer outcomes?

   And it was in 2017 where I listened carefully to a talk by Lynda Chin, the disgraced head of MD Anderson’s Watson implementation – some $62M or $40M spent with plenty of questions around it. While the talk was very interesting – Watson’s ML tested the limits of expert human diagnosis, where human judgement is variable at the edges – the controversy around it didn’t help sell Watson Health to the larger set of healthcare potential customers.

   Later that year, an analyst said “Watson is a joke”, and this was just the beginning of the end. IIRC IBM invested some $15B into Watson Health (as of 2015 per this Aug 2018 WSJ piece and another $5B from 2015 to 2018 when the article was written).

   Thus for $20B what was their return?

   I’ll have to see how I can get a copy of the STAT+ piece linked to in the tweet – a sad end to realizing the promise of personalized medicine for cancer.

   Don’t get me wrong, personalized medicine is here to stay, and cancer is one of its most remarkable beneficiaries – just not in the AI/ML way originally envisioned by IBM.

   ∞ transit umbra, lux permanet ☥
   Submission Statement

   This twitter thread is interesting commentary on IBM’s decision. What I find remarkable about it is that other people are succeeding with AI & healthcare in numerous areas. I wonder if IBM’s misstep was more to do with them being an old, large company. Alphabet’s DeepMind still seems to be powering ahead in this field. It doesn’t feel like IBM’s failure has any long term significance for the field of AI & healthcare.

   EDIT/CORRECTION: The headline is partially misleading. IBM is retaining Watson tech for other purposes and only selling off the healthcare side of the business.

   kjuneja
   ·
   3 days ago
   The problem with AI in the many Healthcare decisions is that being wrong can literally be deadly.

   A 95% accuracy and precision isn’t good enough, and most AI models struggle to even get to 95% due to lack of clean source data in Healthcare

   AI models are easy in adtech or sales where the cost of being wrong is basically 0

   IBM has sold off Watson at a steep discount, and is exiting the AI/Healthcare field.
   reddit.com • 2 min read
   Larry Bernstein sent the following message at 9:10 PM
   View Larry’s profile
   Larry Bernstein
   Larry Bernstein 9:10 PM
   It is no surprise. I told many years ago that they didn’t understand the problem. Perry Seamonds was on track.

   Larry
   Aviva Lev-Ari, PhD, RN sent the following messages at 9:36 PM
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 9:36 PM
   I understand
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 9:43 PM
   We need you Dr. Larry to look at all the attachment added to this string of Messages and to advise LPBI Group – How which of its Intellectual Property Assets would provide COMPLEMENTARITY to the new owners of WATSON Health, Private equity San Francisco based, Francisco Partners.

   I wish to explore if they may be interested in our Journal archive 6,200 articles 70% citations, our Books, conference proceedings. gallery of Biological Images, results of Text Analysis with Natural Language Processing Wolfram’s NLP Software
   THURSDAY
   Larry Bernstein sent the following message at 10:22 AM
   View Larry’s profile
   Larry Bernstein
   Larry Bernstein 10:22 AM
   I have read the preceding statements. I don’t see the especially interesting observations of the first commentator, although I do think that our documents should be of interest because they give a perspective that the physician might have an interest in thinking about some relationship to making a decision.

   t think that the statement about 95% has any relevance because 100% will not be achievable in my lifetime or longer. We are dealing with enormous complexity, and the molecular interactions within the cancer cell or its neighbors is difficult to navigate. I am almost in agreement with the Nobel Physicist who that a complete understanding of cellular processes is unattainable, but it is truly amazing what has been accomplished.

   What I observed over a decade ago was that (1) the blood bank and transfusion was not even included in the most highly trusted medical computer at Harvard and at Yale. The President of Yale Medical School at some time speaking at Bridgeport Hospital joked about the “student” designed computer before the purchase of the most highly honored system., which lacks the blood bank. We then had a separate computer for the blood bank. The matter of the pharmacy was another issue. Then there were complaints from physicians about the nurses use and physician access.

   My personal opthalmologist had studied under a Nobel Laureate in chemistry in New York before proceeding in his medical career. He built Bridgeport Hospital’s laboratory computer, the best in the state for some years. I made a document some years ago identifying key requirements. I also went to Kansas City, Kansas where the prized computer company was dealing with the University of Kansas. Masahiro Chiga was the lab director and we met with the engineers. Their only focus was selling to hospitals. Mas made a computer for the laboratory that served the medical staff.

   I don’t remember the physician years ago who designed a medical computer that was very good, but it also required a full-time person to manage it.

   We are dealing with high complexity and evolving medical knowledge. That is the only matter at hand.

   Larry
   Aviva Lev-Ari, PhD, RN sent the following message at 3:15 PM
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 3:15 PM
   Thank you Dr. Larry for your comments as a Clinician and leading pathologist at top hospitals in the US.

   I need to make the case:
   HOW are the LPBI Intellectual Property Assets complimentary to WATSON Health existing five Databases and Analytics (SPSS and other).

   IF the core content id PUBMED – How 1.0 LPBI Group’s, 2012-2020:
   – 6,200 Journal articles with 2.2 Million VIEWS, – 18 Books in Medicine in 5 specialties of Medicine with 140,000 page downloads,
   – 100 e-Proceedings of Biotech and Medical Conference we covered in Real Time by Invitation and 40 Tweet Collections at these 100 Conferences
   – +6,200 Biological Imaging embedded in original text converting them to Prior Art artifacts, selected by Experts for their articles.

   2.0 LPBI, 2021-2025 – bring to the Table:
   – Text Analysis with Natural Language Processing (NLP) and Machine Learning (ML)
   -Spanish eTOCs
   – Blockchain platform for Content Monetization
   – Molecular design with PRosettaC software for Galectins PROTACs

   HOW ALL OF THE ABOVE CAN BE PRESENTED as VALUE ADDED and COMPLIMENTARY making the existing WATSOM mode successful than it was and charting for it a NEW future.

   THESE IS WHERE WE NEED THE HELP of each of the addressees to this communication string.

   EACH ONE needs to contribute. I stated the goal, above.

   Thank you
   John F. McCarthy sent the following message at 4:38 PM
   View John F.’s profile
   John F. McCarthyStatus is reachable
   John F. McCarthy 4:38 PM
   Without a clear idea of the direction Francisco is planning on taking the IBM Watson Healthcare assets, it is difficult to predict which of LPBI’s assets would be of value to them. I agree that a gap analysis comparing Watson with LPBI would be be informative and might provide additional insight into how combining these 2 data sources might increase the value of Francisco’s acquisitions. While the current draft presentation prepared by Mr. La Cruz does a great job of introducing the LPBI team,, their strengths, and LPBI asset classes, it provides more sizzle (potential) than steak and I believe would not be all that convincing to a potential acquirer. I think the idea of a SWOT analysis would be very insightful if we knew Francisco’s target application for this acquisition. Since they acquired IBM’s healthcare assets and not the Watson analytical engine, are they in the market for a new analytical platform of just improved content? LPBI has potentially valuable content but, only fairly high level correlations among concepts without any causal associations or documented use cases for its assets. A noted earlier regarding Watson “a question they had not a good answer for: was there any peer-reviewed publication they could show me where Watson could help improve diagnosed cancer outcomes? ” I believe the same question could be asked with respect to LPBI assets. While we have potentially valuable content, without data supporting this belief it might be a hard sell.
   Seen by John F. McCarthy at 4:38 PM.
   Aviva Lev-Ari, PhD, RN sent the following messages at 5:20 PM
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 5:20 PM
   I believe that USE CASES are not relevant
   to LPBI because our products are intermediate products not final products

   No one buys Portfolio of IP Assets for having use cases or having on going revenues beyond Royalties which is the ONLY International currency for Intellectual Property.

   Portfolio of iP Assets experience Transfer of OWNERSHIP ONLY based on REPUTATION

   Facts in support of LPBI e-Reputation are:

   – 2.2Million views of 6,200 articles
   – 140,000 page downloads of 18 books
   – six books in use at Medical Schools for NEW Curriculum for medical students
   – +18,000 views of top articles
   – +400,000 views of Dr. Larry’s writings – CSO
   – +500,000 views of Aviva’s writings – Founder

   – Twitter account – Official of LPBI Group
   @pharma_BI followed by

   –>> Rank –>> Handle –>> HONORED to be followed by –>> Followers –>> Bio –>> P/I –>> MEDIA

   1 ehl
   JAMA Ed Livingston 9,570 Deputy Editor for Clinical Reviews and Education @JAMA_Current
   Host JAMA Clinical Reviews P M

   2 Bayer
   US Bayer US 51,421 This is the official Twitter profile for Bayer in the U.S. Our mission ‘Science For A Better Life’ is focused on People, Plants, & Animals. I

   3
   WeizmannUSA
   Weizmann Institute USA 2,696 Science for the Benefit of Humanity — supporting the humanitarian work of the Weizmann Institute of Science in Israel I

   4 PHSInnovation Partners
   Innovation 1,815 Responsible for the commercial application of the unique capabilities of employees & faculty across PHS including MGH & BWH. Organizer of #WMIF2020 I

   5 PhRMA
   PhRMA 77,730 We represent America’s innovative biopharmaceutical research & biotechnology companies. Subscribe to alerts at https://t.co/29cEjqQwox. @SteveUbl CEO I M

   6 TechnionLive
   Technion Israel 47,997 Technion: Israel Institute of Technology. Over 100 years of commitment to science, technology, innovation & education. I

   7 KeckMedUSC
   Keck Medicine of USC 211,528 500+ internationally renowned doctors at a leading academic medical center keeping you healthy, on track and doing the things you love. #TheKeckEffect I

   8 intermtncancer
   Intermountain Cancer 13,387 Intermountain Cancer Centers serves patients across the nation and the world. Our goal is to help patients with cancer live the healthiest lives possible! I this is the client in UT

   9 TechnionT3
   Technion T³ 16,260 Technion IIT technology transfer office. Israel science, technology, innovation. Facebook: https://t.co/kIU5sB4wPP I

   10 HadasitBio
   Hadasit Bio-Holdings 1,261 A publicly traded subsidiary (OTCBB: HADSY) of the Hadassah University Hospital, Israel’s foremost medical research center, promoting medical breakthroughs. I

   11 MassBio
   MassBio 18,822 MassBio is committed to advancing MA’s leadership in the life sciences to grow the industry, add value to the healthcare system & improve patient lives. I M

   12 Thomas_Wilckens
   Dr. Thomas Wilckens 3,442 MD #PrecisionMedicine leader: Changing the way we diagnose, treat and eventually prevent disease #Innovation #Healthcare #Medicine #MachineLearning #AI #omics P
   Total 455,929

   Facts in support of LPBI’s Founder’s e-Reputation are:

   Twitter Account of LPBI’s Founder is:
   @AVIVA1950

   –>> Rank –>> Handle –>> HONORED to be followed by –>> Followers –>> Bio –>> P/I –>> MEDIA

   1 broadinstitute
   Broad Institute @ Harvard & MIT 62,385 A unique, collaborative community pioneering a new model of biomedical science I

   2 Bayer
   US Bayer US 51,427 This is the official Twitter profile for Bayer in the U.S. Our mission ‘Science For A Better Life’ is focused on People, Plants, & Animals. I

   3 TechnionLive
   Technion Israel 48,001 Technion~ Israel Institute of Technology. Over 100 years of commitment to science, technology, innovation & education. I

   4 BioWorld
   BioWorld 33,766 Biopharma’s trusted news source. Lynn Yoffee, Jennifer Boggs, Anette Breindl, Michael Fitzhugh, Lee Landenberger, Randy Osborne, Mari Serebrov, Peter Winter I M

   5 BellLabs
   Bell Labs 28,007 World-renowned #innovation research arm of @Nokia. We have invented many technologies that underpin communications networks and all digital devices and systems. I

   6 PHSInnovation
   Partners Innovation 1,815 Responsible for the commercial application of the unique capabilities of employees & faculty across PHS including MGH & BWH. Organizer of #WMIF2020 I

   7 TechnionT3
   Technion T³ 16,259 Technion IIT technology transfer office. Israel science, technology, innovation. Facebook: https://t.co/kIU5sB4wPP I
   8 BCM_CVRI
   BCM_CVRI 2,251 The Official Twitter Account for the Baylor College of Medicine Cardiovascular Research Institute I

   9 pierrepinna
   Pinna Pierre 53,378 Founder CEO IPFConline Digital Innovations @ipfconline1
   Computer Science Engineer #BigData #Analytics #eLearning #AI #Ethics #MachineLearning #DigitalMarketing P

   10 MIT_Spectrum
   MIT Spectrum 7,492 Connect to the vision, impact, and exceptional community of the Massachusetts Institute of Technology. Share your stories with #MITBetterWorld. I

   11 CMichaelGibson
   C. Michael Gibson MD 444,802 [Scientist and Author] P

   12 TED_TALKS
   Ted Talks 677,268 Fan Created Account – sharing our love for Ted and TedX Talks I

   Total 1,426,851
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 6:46 PM
   If you transfer ownership over a Real Estate Asset the exchange is of Down payment in Cash and a Mortgage contract

   If you transfer ownership over a Portfolio of Intellectual Property Assets
   the exchange is Royalties NOT Cash, Mortgage contract, bank notes

   LPBI is a content creator without a ledger to sell content

   2.0 LPBI is building a Blockchain IT platform for content monetization – upon indexing of ALL our IP Assets, their storage in the Blockchain and NLP interface developed – CONTENT MONETIZATION will take place Globally including our content in S

   NO ONE EXPECTS a powerhouse of contnet creating to sell content if ONLY an authoring platform is in place.

   NO ONE EXPECTS Use cases if no consulting services are pursued !!!!!
   Larry Bernstein sent the following message at 7:43 PM
   View Larry’s profile
   Larry Bernstein
   Larry Bernstein 7:43 PM
   I don’t get the point.

   Larry
   Aviva Lev-Ari, PhD, RN sent the following messages at 9:12 PM
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 9:12 PM
   What you do not get?

   If one says:
   Show me Use Case of LPBI contents:

   My answer is:
   LPBI Group NEVER intended or was engaged in consulting services THEREFORE there are no Use Cases of B2B, names of clients such as Big Pharma, Healthcare Insurance that LPBI Group pursued to obtain Consulting contracts.

   If one says:
   Show me the EXTENT of the engagement with your content

   My answer is:
   1. Journal – 2.2Million Views
   2. Books – 140,000 page downloads
   3. Twitter Engagement – See here
   https://pharmaceuticalintelligence.com/2019-vista/comparative-analysis-of-engagement-for-four-twitter-accounts-kdnuggets-big-data-gilpress-forbes-pharma_bi-aviva1950/
   4. Ranking as Influencer

   Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
   pharmaceuticalintelligence.com • 1 min read
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 9:14 PM
   2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19 via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19
   By “Mentions” – Ranked #4: @pharma_BI and
   By “Tweets” – Ranked #2: @AVIVA1950
   via NodeXL http://bit.ly/2KB6cPN

   By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI
   https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

   AND

   For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers], 2019 – 2020

   https://pharmaceuticalintelligence.com/2019/08/06/twitter-analytics-engagement-rate-link-clicks-retweets-likes-replies-tweet-highlights-tweets-impressions-profile-visits-mentions-new-followers-for-aviva1950-founder-lpbi-group-ph/
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 9:22 PM
   It is about time that ALL ACTIVE LPBI Teams members and Affiliates will be FAMILIAR with the FACTS

   IN A LIFETIME I would not dare to know little on a subject and express such BOLD views !!!

   I do my homework 1st then I ask questions to get all the ducks in a row then recursive again and again THEN voice my opinion with a Disclaimer: In light of the following facts [enumated a LIST of facts] I concluded that …
   I defend my view by
   You added Sudipta Saha to this conversation
   TODAY
   Larry Bernstein sent the following messages at 1:11 AM
   View Larry’s profile
   Larry Bernstein
   Larry Bernstein 1:11 AM
   I confess that I am awed by Aviva’s work over the last many years. What I have expressed is not so comprehensive. The issue is not just a contribution to CANCER diagnosis. The product we have worked on has a possible connection to diagnostic facilitation. The LPBI has to be triggered in diagnosis by the signaling in the medical engine by terms or statements that elicit its facilitation. This has been the key to how a laboratory information system could be keyed to respond to abnormal values or to related abnormal values. I published a paper 10 years ago with the chairman of mathematics on the diagnosis using hematology laboratory results. I did not have sufficient data for clinical chemistry results. The extension of such work could be a connection to relevant literature by LPBI.

   Larry
   View Larry’s profile
   Larry Bernstein
   Larry Bernstein 1:12 AM
   It would be helpful for such to tie together the pharmaceutical aspects.
   Seen by Stephen J. Williams, Ph.D. at 1:33 AM.
   Aviva Lev-Ari, PhD, RN sent the following message at 4:08 AM
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 4:08 AM
   Thank you Dr. Larry.

   John McCarty had cited another Reddit post, see above, asking:

   “Show me one case where WATSON Health was used in detected of Cancer diagnosis”

   WATSON Health is an INTERMEDIATE
   OR
   INTERMEDIARY Information System

   EVERY HOSPITAL that was signed up as a paying customer of IBM WATSON Health was used by oncologists and by MANY Hospital physicians involved in Cancer diagnosis.

   You get CHEK2 mutation
   to a Genomic testing you ordered for your cancer patient
   • you submit a query to WATSON Health – you get all PubMed articles
   • you submit a query to
   LPBI Search Box on our website – you get CURATIONS on CHEK2

   Indeed, p53, BRCA1/2, KRAS, BRAF and EGFR and other are very well covered by LPBI

   FOR THE RECORD:

   Aviva’s contributions are on Cardiovascular NOT ON CANCER

   The Esteemed Team on Cancer at LPBI, who published 2 books on Cancer WERE:
   • Dr. Williams
   • Dr. Larry
   • Dr. Dror Nir, Dr. Ziv Ravid, Dr. Ritu Saxena, Dr. Tilda Barliya
   Seen by Sudipta Saha at 6:57 AM. Seen by Gregory Piatetsky-Shapiro at 8:36 AM.
   Larry Bernstein sent the following message at 9:49 AM
   View Larry’s profile
   Larry Bernstein
   Larry Bernstein 9:49 AM
   My vision is not that LPBI would just be a lookup site. I see it as a link intimately connected with The diagnostic process. I’ll see if I can contact Dr. Perry Seamonds. His sister is a good friend and capable in this as well (Bette Seamonds).

   Larry
   Seen by Larry Bernstein at 9:49 AM. Seen by Ofer Markman at 9:54 AM.
   Aviva Lev-Ari, PhD, RN sent the following message at 9:59 AM
   View Aviva’s profile
   Aviva Lev-Ari, PhD, RNStatus is online
   Aviva Lev-Ari, PhD, RN 9:59 AM
   WHAT MATTERS IS:
   What to you find WHEN you look up

   IF LPBI’s content will be integrated
   THEN
   a search FETCHES our curations vs a DUMP of experiments and clinical Trials from the most recent to the oldest, top 100 publications

   For Disgnosis the physician needs both
   START with the curation
   CONTINUE withPubMed

   Versus
   GET LOST IN PubMed and never reach ENLIGHTENED Expert Interpretation

   Loading...

   
   
3. on January 28, 2022 at 12:28 PM | Reply 2012pharmaceutical

   ONE EXAMPLE of what one gains if accessing LPBI Group’s IP:

   A little background on the construction and design of this e-Book is warranted.

   In discussion with the Senior Editor Larry H. Bernstein M.D. FCAP and other editors, Tilda Barliya, Ph.D., Ritu Saxena, Ph.D. and Aviva Lev-Ari , Ph.D. R.N., the Senior Editor felt that, instead of producing a cancer book which only contains topical chapters (such as therapies used in each different cancer type), it was decided that, the volume one of this two e-Book Series:

   Series C: e-Books on Cancer & Oncology

   which contains: Volume 1 and Volume 2, should explain the paradigm shift from Cancer as disparate diseases of individual tissue patho-physiologies to the new view of Cancer as a disease involving distinct biotargets which can be targeted in a precision manner.

   This paradigm shift is evident in the way in which new onco-therapies are investigated and approved, where a drug is approved for a certain biotarget like a mutant BRAF versus a certain tumor type, for instance, a pancreatic adenocarcinoma. Therefore, the Senior Editor felt the first few chapters should be dedicated to the reader’s understanding the basic biology behind the oncogenic process, with later chapters dealing with individual and more advanced topics.

   In the voice of the Senior Editor Larry H. Bernstein M.D. FCAP

   The evolution of progress we have achieved in cancer research, diagnosis, and therapeutics has originated from an emergence of scientific disciplines and the focus on cancer has been recent.
   and
   A multidisciplinary approach has led us to a unique multidisciplinary or systems view of cancer, with different fields of study offering their unique expertise, contributions, and viewpoints on the etiology of cancer. Diverse fields in immunology, biology, biochemistry, toxicology, molecular biology, virology, mathematics, social activism and policy, and engineering have made such important contributions to our understanding of cancer, that without cooperation among these diverse fields our knowledge of cancer would never had evolved as it has.

   And in the book’s Epilogue (Larry H. Bernstein M.D. FCAP)

   This volume and its content have been conceived and organized to capture the organized events that emerge in embryological development, leading to the major organ systems that we recognize anatomically and physiologically as an integrated being. We capture the dynamic interactions between the systems under stress that are elicited by cytokine-driven hormonal responses, long thought to be circulatory and multisystem, that affect the major compartments of fat and lean body mass, and are as much the drivers of metabolic pathway changes that emerge as epigenetics, without disregarding primary genetic diseases.
   The greatest difficulty in organizing such a work is in whether it is to be merely a compilation of cancer expression organized by organ systems, or whether it is to capture developing concepts of underlying stem cell expressed changes that were once referred to as “dedifferentiation”. In proceeding through the stages of neoplastic transformation, there occur adaptive local changes in cellular utilization of anabolic and catabolic pathways, and a retention or partial retention of functional specificities.
   This effectively results in the same cancer types not all fitting into the same “shoe”. There is a sequential loss of identity associated with cell migration, cell-cell interactions with underlying stroma, and metastasis, but cells may still retain identifying “signatures” in microRNA combinatorial patterns. The story is still incomplete, with gaps in our knowledge that challenge the imagination.

   And in the voice of another editor of this e-Book: Stephen J. Williams, Ph.D.
   “This e-Book highlights some of the recent trends and discoveries in cancer research and cancer treatment, with particular attention how new technological and informatics advancements have ushered in paradigm shifts in how we think about, diagnosing, and treating cancer. The book is organized with the 8 hallmarks of cancer in mind, concepts which are governing principles of cancer from Drs. Hanahan and Weinberg (Hallmarks of Cancer) [13, 14].
   1. Maintaining Proliferative Signals
   2. Avoiding Immune Destruction
   3. Evading Growth Suppressors
   4. Resisting Cell Death
   5. Becoming Immortal
   6. Angiogenesis
   7. Deregulating Cellular Energy
   8. Activating Invasion and Metastasis
   Therefore, the reader is asked to understand how each of these underlying principles are being translated to current breakthrough discoveries, in association with the basic biological knowledge we have amassed through diligent research and how these principals and latest research can be used by the next generation of cancer scientist and oncologist to provide the future breakthroughs. As the past basic research had provided a new platform for the era of genomics in oncology, it is up to this next generation of scientists and oncologists to provide the basic research for the next platform which will create the future breakthroughs to combat this still deadly disease.”
   This flow of the book, meant to be read sequentially and in its entirety, from basic biology to more applied topics, is evident in the striking difference in hypergraph patterns of Chapters 1-6 versus 8-12 (with Chapter 7 an intermediate pattern). It is also striking that, if one just randomly walks through this book or the hypergraphs, this structure of the e-Book would not be as apparent as it does while reading it sequentially from the important Preface and Introduction through the Chapters in order.

   Loading...